Pages

.

Showing posts with label Expands. Show all posts
Showing posts with label Expands. Show all posts

Millennium Laboratories Expands Pharmacogenetic Test to Help Clinicians Prescribe the Right Medicine at the Right Dose

Millennium PGT. (PRNewsFoto/Millennium Laboratories, LLC)Millennium Laboratories. (PRNewsFoto/Millennium Laboratories, LLC)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";SAN DIEGO, July 17, 2014 /PRNewswire/ -- Millennium Laboratories announced today that it has expanded its pharmacogenetic test (Millennium PGTSM) to include seven additional genes. The expanded test gives clinicians additional, objective information, based on patients' own genetics to help determine their potential response to a broad list of medications commonly prescribed across four key therapeutic areas, including pain, mental health, addiction and cardiovascular therapy.

Millennium PGT now analyzes clinically relevant genetic variants for 11 genes related to medication response to help clinicians individualize prescribing decisions. The Millennium Analysis of Patient Phenotype (MAPP®) Report provides clinicians with evidence based and clinically actionable information to support medication decisions for over 30 commonly prescribed medications across 14 medication classes. The MAPP Report also includes information for 20 medications with pharmacogenetic information or specific recommendations related to use in their U.S. Food and Drug Administration approved labels.  

"Millennium is providing clinical tools for improving care for all patients, and through investments in the newest technologies, we have delivered on that promise with our expanded PGT offering," said Chief Executive Officer, Brock Hardaway. "This milestone allows us to continue fulfilling a crucial need in health care, and offers additional tools that may help providers make more effective, individualized medication choices to get their patients on the path to wellness faster."

This saliva-based test helps clinicians determine, based on genetics, which medications are more likely to work for an individual patient, while helping them to avoid prescribing those more likely to cause adverse reactions. Millennium PGT helps health care providers minimize trial and error prescribing potentially shortening the time it takes for patients to feel better.

"It is very good to know it's the right drug, and it's very good to know that you're giving the right dose, and it's good to know that that patient is going to respond in the way you hope," said Dr. Manya Helman, family practice physician, Salem, Ore. "To be able to give the right drug, in the right dose, to right patient is exactly what our goal is."

In addition to the core offerings of CYP2D6, CYP2C19, CYP2B6, and UGT2B15, this expansion will significantly broaden Millennium's PGT menu to include CYP2C9, CYP3A4, CYP3A5, as well as VKORC1, COMT, MTHFR and OPRM1. Paired with PGT ConsultSM, a mobile application that provides evidence-based clinical decision support to health care providers, Millennium PGT is helping clinicians optimize patient care. 

About Millennium PGT
Millennium PGT is a laboratory developed pharmacogenetic test that analyzes clinically important genetic variations associated with how patients may respond to many commonly prescribed medicines. Millennium PGT is a saliva based test that provides clinicians with objective information that may help them individualize medication treatment decisions.

Millennium PGT is paired with the MAPP® Report, which provides clinicians with actionable information, based on a patient's own genetics, about their potential response to over 30 medications prescribed across four key therapeutic areas: pain, mental health, addiction and cardiovascular therapy. Together with PGT Consult, a mobile application that provides evidence-based clinical decision support, the combination of tools helps clinicians individualize medications to their patient's unique genetics, maximizing the opportunity for successful outcomes.

About Millennium Laboratories
Millennium Laboratories, a leader in the science of medication monitoring and pharmacogenetics, is transforming the way health care professionals monitor and manage their patients' medication therapy. Through the use of advanced technology, supported by research and education, Millennium helps practitioners personalize care for patients. Building on this strong foundation, Millennium aims to expand its impact by helping more people affected by chronic illnesses and dedicating itself to filling a crucial unmet need in health care. More information can be found at www.millenniumlabs.com.

Logo - http://photos.prnewswire.com/prnh/20140716/127829
Logo - http://photos.prnewswire.com/prnh/20120224/MM59482LOGO

SOURCE Millennium Laboratories, LLC

RELATED LINKS
http://www.becausepainmatters.com

reade more... Résuméabuiyad

Protein Metrics Expands Biopharmaceutical Software Suite with Launch of Byomap™ Software

Protein Metrics Byomap(TM) software, developed in close collaboration with biopharmaceutical researchers, facilitates quick annotation of peptide maps and rapid, quantitative comparison of multiple data traces against a reference material. ...jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";SAN CARLOS, Calif., March 24, 2014 /PRNewswire-iReach/ -- Protein Metrics Inc., a leading provider of software for rapid and thorough protein characterization, today announced the release of Byomap™ software for advanced peptide mapping. Byomap facilitates quick annotation of peptidemaps and rapid, quantitative comparison of multiple data traces against a reference material. Byomap is an extension of Protein Metrics' biopharmaceutical suite of products that includes their Byologic™ software, which enables researchers to confidently characterize their product down to trace components identifying degadants, impurities, post-translational modifications and sequence variants.

(Photo: http://photos.prnewswire.com/prnh/20140324/MN87673)

"We are excited to expands our biopharmaceutical portfolio and provide a new, advanced peptide mapping tool to help biopharmaceutical researchers characterize their therapeutic proteins," said Chris Becker, Ph.D., President and CEO of Protein Metrics. "Byomap's convenient annotation and comparison capabilities enable our customers to quickly report on comparability and advance their Quality by Design (QbD) initiatives to track quality attributes as their products move through development."

Originally developed in close collaboration with biopharmaceutical researchers, Byomap begins the quantitative evaluation of chromatograms by first detecting peaks, then performing automatic baseline and peak area determinations. Annotation is rapid with the aid of novel visualization tools. Byomap can simultaneously align and quantitatively compare up to ten peptide maps to an annotated reference map, flagging peaks with out-of-tolerance intensities. It can also be used to analyze other types of chromatograms such as for detached glycans. The software has sophisticated export features for figures and tables that can be used directly in regulatory filings.

About Protein Metrics

Protein Metrics is a privately held software company serving biopharmaceutical development professionals and proteomics researchers. The company focuses on the analysis of mass spectrometric and other analytical data on proteins and glycans. Seeking to ensure that software to analyze mass spec and other analytical data keeps pace with the rapid advances in analytical instrumentation, Protein Metrics leverages its experience in analytical chemistry, bioinformatics, and computer science to make analytical results more complete, sensitive, accurate, and easier to achieve. Protein Metrics products are built on collaborations with pharmaceutical research scientists and years of research on proteins and glycans. The company is headquartered in San Carlos, California. For more information, visit www.proteinmetrics.com.

Media Contact: Eric Carlson, Protein Metrics, Inc., 408-600-5540, carlson@proteinmetrics.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Protein Metrics, Inc.

RELATED LINKS
http://www.proteinmetrics.com

reade more... Résuméabuiyad